Clinical trials: Anaplastic Lymphoma Kinase
Solid Tumor
Study of an Investigational Drug, ASP3026, in Patients With Solid Tumors
A study to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors).
- Trial name
- NCT01401504
- Testing
- ASP3026
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Astellas Pharma Inc
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
Managed Access Programs for LDK378, Ceritinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
- Trial name
- NCT05100134
- Testing
- ceritinib
- Sponsor
- Novartis Pharmaceuticals
Non-Small-Cell Lung Carcinoma
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
This study aims to understand patient profiles, treatment patterns, and clinical outcomes among ALK-positive NSCLC patients treated with alectinib, and post-alectinib treatment patterns and outcomes.
- Trial name
- NCT04351334
- Testing
- Alectinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Pfizer
Solid Tumors, Lymphomas
A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer, including: 1. Anaplastic lymphoma kinase (ALK) 2.
- Trial name
- NCT02048488
- Testing
- TSR-011
- Where
- 15 sites in United States, Poland and 3 more
- Volunteers
- 72 people
- Sponsor
- Tesaro, Inc.
ALK-positive NSCLC
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
- Trial name
- NCT02393625
- Testing
- Ceritinib (LDK378), Nivolumab
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small-Cell Lung Carcinoma
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment.
- Trial name
- NCT01801111
- Testing
- Erlotinib, Alectinib
- Where
- 84 sites in United States, Australia and 14 more
- Volunteers
- 138 people
- Sponsor
- Hoffmann-La Roche
Cancers With NTRK, ROS1, or ALK Gene Fusions
Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions
Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for…
- Trial name
- NCT03066661
- Testing
- Entrectinib
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase
A Study of Brigatinib to Treat Adults With Anaplastic Lymphoma Kinase (ALK) Positive Metastatic Non Small Cell Lung Cancer (NSCLC)
The aims of the study are to assess the safety profile of brigatinib and the clinical response rates in adults with Anaplastic Lymphoma Kinase (ALK)-Positive Metastatic Non Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT04887519
- Testing
- No Intervention
- Where
- Argentina
- Volunteers
- 39 people
- Sponsor
- Takeda
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR…
- Trial name
- NCT06074588
- Testing
- Sacituzumab tirumotecan, Docetaxel, Pemetrexed
- Where
- 195 sites in United States, Australia and 23 more
- Volunteers
- 556 people
- Sponsor
- Merck Sharp & Dohme LLC
ALK-positive NSCLC
Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
To evaluate the efficacy and safety of TQ-B3139 in subjects with ALK-positive non-small cell lung cancer that have demonstrated progression during or after crizotinib treatment whether or not previously treated with cytotoxic…
- Trial name
- NCT04056572
- Testing
- TQ-B3139
- Where
- 2 sites in China
- Volunteers
- 135 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Carcinoma, Non-Small-Cell Lung
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Demonstrate feasibility of detection of EML4-ALK fusion transcripts and T790M EGFR mutation from exosomes in the circulation of Non-Small Cell Lung Cancer (NSCLS) patients.
- Trial name
- NCT03236675
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Carcinoma, Non-Small-Cell Lung
A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of brigatinib (AP26113) in participants with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose…
- Trial name
- NCT02094573
- Testing
- Brigatinib
- Volunteers
- 222 people
- Sponsor
- Ariad Pharmaceuticals
ALK Positive Non-small Cell Lung Cancer
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer
This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as…
- Trial name
- NCT07617337
- Testing
- AQUA07, Lorlatinib
- Where
- 7 sites in United States, Japan
- Volunteers
- 102 people
- Sponsor
- Chugai Pharmaceutical
Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
PF-02341066 may work in cancer by blocking the cell growth, migration and invasion of tumor cells. PF-02341066 is a new class of drugs called c-Met/Hepatocyte growth factor receptor tyrosine kinase inhibitors.
- Conditions
- Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma
- Trial name
- PROFILE 1001 (NCT00585195)
- Testing
- PF-02341066, Rifampin, Itraconazole
- Where
- 29 sites in United States, Australia and 2 more
- Volunteers
- 596 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene.
- Trial name
- NCT00932451
- Testing
- PF-02341066
- Where
- 280 sites in United States, Australia and 20 more
- Volunteers
- 1,069 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer
This is an open-label multi-center Phase 2 efficacy and safety study of crizotinib in East Asian patients with advanced Non-Squamous NSCLC harboring a translocation or inversion event involving the ALK gene locus who have…
- Trial name
- NCT01500824
- Testing
- Crizotinib
- Sponsor
- Pfizer
Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Estimation of the Maximum tolerated dose (MTD) and/or Recommended dose (RD) of LDK378 as a single agent when administered orally to Japanese patients with tumors characterized by genetic alterations in anaplastic lymphoma kinase…
- Trial name
- NCT01634763
- Testing
- LDK378
- Where
- 3 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer (NSCLC)
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the…
- Trial name
- Brilliant (NCT05721950)
- Testing
- Brigatinib
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Takeda